查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1763972

代謝組檢測市場－全球產業規模、佔有率、趨勢、機會和預測，按分析物、按疾病、按最終用途（實驗室、PoC、PoC）、按地區和競爭細分，2020 年至 2030 年

Metabolic Panel Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Analytes, By Disease, By End Use (Laboratory, PoC, PoC ), By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球代謝組檢測市值為 124.1 億美元，預計到 2030 年將達到 215.6 億美元，預測期內的複合年成長率為 9.62%。隨著全球醫療保健系統優先考慮早期診斷和預防性醫療保健，市場正在穩步擴張。綜合代謝組 (CMP) 檢測已成為常規診斷工具，可提供有關腎臟和肝臟功能、血糖和電解質平衡的資訊。糖尿病、腎臟疾病和肝功能障礙等代謝紊亂的盛行率不斷上升，使得 CMP 檢測在臨床診斷中至關重要。此外，人口老化和常規健康監測日益重要，正在擴大接受這些檢測的患者群。 CMP 檢測現在是住院和門診健康體檢的常規部分。實驗室自動化和數位資料整合等技術進步正在提高檢測效率和準確性。個人化醫療和即時診斷設備日益普及，尤其是在緊急護理和偏遠地區，這使得這些診斷變得更容易獲得，並促進了整體市場的成長。

市場概覽
預測期 2026-2030
2024年市場規模 124.1億美元
2030年市場規模 215.6億美元
2025-2030 年複合年成長率 9.62%
成長最快的領域 糖尿病
最大的市場 北美洲

關鍵市場促進因素

慢性和代謝性疾病盛行率上升

主要市場挑戰

先進診斷設備成本高昂

主要市場趨勢

轉向個人化和預防性醫療保健

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球代謝組檢測市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依分析物（K+、Na+、Cl-、CO2、葡萄糖、尿素氮、肌酸酐、Ca++、白蛋白、總蛋白、鹼性磷酸酶、丙氨酸氨基轉移酶、天門冬胺酸氨基轉移酶、總膽紅素）
    • 依疾病（腎臟病、肝病、糖尿病、其他）
    • 依最終用途（實驗室、PoC、PoC（儀器））
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美代謝組檢測市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲代謝組檢測市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太代謝組檢測市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲代謝組檢測市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲代謝組檢測市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Abbott Laboratories
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings Limited
  • Sonic Healthcare Limited
  • Unipath Specialty Laboratory Limited
  • SYNLAB International GmbH
  • ARUP Laboratories
  • Genoptix, Inc.
  • Nova Medical, Inc.
  • Mindray Medical International Limited

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 29925

The Global Metabolic Panel Testing Market was valued at USD 12.41 billion in 2024 and is projected to reach USD 21.56 billion by 2030, growing at a CAGR of 9.62% during the forecast period. The market is expanding steadily as healthcare systems globally prioritize early diagnosis and preventive healthcare. Comprehensive Metabolic Panel (CMP) testing has become a routine diagnostic tool, offering insights into kidney and liver function, blood glucose, and electrolyte balance. The increasing prevalence of metabolic disorders such as diabetes, kidney disease, and liver dysfunction has made CMP tests vital in clinical diagnostics. Additionally, an aging population and the rising importance of routine health monitoring are enlarging the patient base for these tests. CMP testing is now a regular part of wellness checkups in both inpatient and outpatient settings. Technological advancements, including laboratory automation and digital data integration, are enhancing testing efficiency and accuracy. The rising popularity of personalized medicine and point-of-care testing devices, particularly in urgent care and remote areas, is making these diagnostics more accessible and contributing to overall market growth.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 12.41 Billion
Market Size 2030USD 21.56 Billion
CAGR 2025-20309.62%
Fastest Growing SegmentDiabetes
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Chronic and Metabolic Disorders

The growing incidence of chronic and metabolic disorders is a major driver of the Global Metabolic Panel Testing Market. Noncommunicable diseases (NCDs) such as cardiovascular conditions, cancer, chronic respiratory diseases, and diabetes are now the leading causes of mortality globally. In 2021, NCDs were responsible for 75% of all deaths worldwide, with cardiovascular diseases causing 19 million deaths, cancers 10 million, chronic respiratory diseases 4 million, and diabetes over 2 million. Metabolic disorders like hypertension, high blood sugar, and elevated lipid levels are critical risk factors for these conditions. A global meta-analysis involving 28 million individuals found that the prevalence of metabolic syndrome ranges from 12.5% to 31.4%, with higher rates in the Eastern Mediterranean and the Americas. Many of these conditions remain undiagnosed until complications arise, highlighting the need for regular metabolic screening through CMP tests for early detection and preventive intervention.

Key Market Challenges

High Cost of Advanced Diagnostic Equipment

The cost associated with acquiring and operating advanced diagnostic equipment remains a key challenge in the Global Metabolic Panel Testing Market. Accurate CMP testing relies on sophisticated analyzers capable of evaluating multiple biomarkers, including glucose levels, enzymes, and electrolytes. These instruments involve substantial capital investment and require ongoing expenditure on maintenance and consumables. For smaller or resource-limited healthcare facilities, especially in developing regions, such expenses can be prohibitive. Smaller diagnostic laboratories may be unable to justify or afford the cost, leading to limited test offerings or dependence on outdated systems with lower accuracy and efficiency. This creates disparities in access to reliable diagnostics across different regions and facility types, posing a challenge to universal healthcare goals.

Key Market Trends

Shift Toward Personalized and Preventive Healthcare

A prominent trend influencing the Global Metabolic Panel Testing Market is the transition toward personalized and preventive healthcare. As healthcare providers increasingly focus on early detection and tailored treatment strategies, CMP testing plays an essential role in identifying metabolic imbalances before clinical symptoms emerge. The ability to detect early signs of conditions such as diabetes and hypertension allows for customized treatment planning, enhancing patient care outcomes. Advances in genomics are further supporting this shift, as genetic profiling is combined with CMP results to develop individualized health management approaches. This integration is fostering a proactive model of care, with the emphasis shifting from disease treatment to early intervention and disease prevention.

Key Market Players

  • Abbott Laboratories
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings Limited
  • Sonic Healthcare Limited
  • Unipath Specialty Laboratory Limited
  • SYNLAB International GmbH
  • ARUP Laboratories
  • Genoptix, Inc.
  • Nova Medical, Inc.
  • Mindray Medical International Limited

Report Scope:

In this report, the Global Metabolic Panel Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metabolic Panel Testing Market, By Analytes:

  • K+
  • Na+
  • Cl-
  • CO2
  • Glucose
  • BUN
  • Creatinine
  • Ca++
  • Albumin
  • Total protein
  • ALP
  • ALT
  • AST
  • Total bilirubin

Metabolic Panel Testing Market, By Disease:

  • Kidney Disease
  • Liver Disease
  • Diabetes
  • Others

Metabolic Panel Testing Market, By End Use:

  • Laboratory
  • PoC
  • PoC (Instruments)

Metabolic Panel Testing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metabolic Panel Testing Market.

Available Customizations:

Global Metabolic Panel Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Metabolic Panel Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Analytes (K+, Na+, Cl-, CO2, Glucose, BUN, Creatinine, Ca++, Albumin, Total protein, ALP, ALT, AST, Total bilirubin)
    • 5.2.2. By Disease (Kidney Disease, Liver Disease, Diabetes, Others)
    • 5.2.3. By End Use (Laboratory, PoC, PoC (Instruments))
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Metabolic Panel Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Analytes
    • 6.2.2. By Disease
    • 6.2.3. By End Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Metabolic Panel Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Analytes
        • 6.3.1.2.2. By Disease
        • 6.3.1.2.3. By End Use
    • 6.3.2. Mexico Metabolic Panel Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Analytes
        • 6.3.2.2.2. By Disease
        • 6.3.2.2.3. By End Use
    • 6.3.3. Canada Metabolic Panel Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Analytes
        • 6.3.3.2.2. By Disease
        • 6.3.3.2.3. By End Use

7. Europe Metabolic Panel Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Analytes
    • 7.2.2. By Disease
    • 7.2.3. By End Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Metabolic Panel Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Analytes
        • 7.3.1.2.2. By Disease
        • 7.3.1.2.3. By End Use
    • 7.3.2. Germany Metabolic Panel Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Analytes
        • 7.3.2.2.2. By Disease
        • 7.3.2.2.3. By End Use
    • 7.3.3. United Kingdom Metabolic Panel Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Analytes
        • 7.3.3.2.2. By Disease
        • 7.3.3.2.3. By End Use
    • 7.3.4. Italy Metabolic Panel Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Analytes
        • 7.3.4.2.2. By Disease
        • 7.3.4.2.3. By End Use
    • 7.3.5. Spain Metabolic Panel Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Analytes
        • 7.3.5.2.2. By Disease
        • 7.3.5.2.3. By End Use

8. Asia-Pacific Metabolic Panel Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Analytes
    • 8.2.2. By Disease
    • 8.2.3. By End Use
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Metabolic Panel Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Analytes
        • 8.3.1.2.2. By Disease
        • 8.3.1.2.3. By End Use
    • 8.3.2. India Metabolic Panel Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Analytes
        • 8.3.2.2.2. By Disease
        • 8.3.2.2.3. By End Use
    • 8.3.3. South Korea Metabolic Panel Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Analytes
        • 8.3.3.2.2. By Disease
        • 8.3.3.2.3. By End Use
    • 8.3.4. Japan Metabolic Panel Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Analytes
        • 8.3.4.2.2. By Disease
        • 8.3.4.2.3. By End Use
    • 8.3.5. Australia Metabolic Panel Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Analytes
        • 8.3.5.2.2. By Disease
        • 8.3.5.2.3. By End Use

9. South America Metabolic Panel Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Analytes
    • 9.2.2. By Disease
    • 9.2.3. By End Use
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Metabolic Panel Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Analytes
        • 9.3.1.2.2. By Disease
        • 9.3.1.2.3. By End Use
    • 9.3.2. Argentina Metabolic Panel Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Analytes
        • 9.3.2.2.2. By Disease
        • 9.3.2.2.3. By End Use
    • 9.3.3. Colombia Metabolic Panel Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Analytes
        • 9.3.3.2.2. By Disease
        • 9.3.3.2.3. By End Use

10. Middle East and Africa Metabolic Panel Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Analytes
    • 10.2.2. By Disease
    • 10.2.3. By End Use
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Metabolic Panel Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Analytes
        • 10.3.1.2.2. By Disease
        • 10.3.1.2.3. By End Use
    • 10.3.2. Saudi Arabia Metabolic Panel Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Analytes
        • 10.3.2.2.2. By Disease
        • 10.3.2.2.3. By End Use
    • 10.3.3. UAE Metabolic Panel Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Analytes
        • 10.3.3.2.2. By Disease
        • 10.3.3.2.3. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Abbott Laboratories
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Quest Diagnostics Incorporated
  • 14.3. Laboratory Corporation of America Holdings Limited
  • 14.4. Sonic Healthcare Limited
  • 14.5. Unipath Specialty Laboratory Limited
  • 14.6. SYNLAB International GmbH
  • 14.7. ARUP Laboratories
  • 14.8. Genoptix, Inc.
  • 14.9. Nova Medical, Inc.
  • 14.10. Mindray Medical International Limited

15. Strategic Recommendations

16. About Us & Disclaimer